November 23rd 2024
The Thousand Oaks, Calif., cell therapy manufacturing facility now houses new production suites, updated development labs, and more after expansion.
Tackling Production Challenges through Greater Access to mRNA Technologies
November 27th 2023Chris Spivey, editorial director for Pharmaceutical Technology, discusses messenger RNA (mRNA) advances with Guillaume Roelandts, Head of Products and Marketing, Quantoom Biosciences, at the 11th International mRNA Health Conference in Berlin, Germany.
The Challenges of the Journey from Clinical to Commercial Cell Therapies
October 12th 2023Humberto Vega, PhD, Executive Director, Bristol Myers Squibb, discusses the journey from clinical to commercial cell therapies as a part of his session, "Successfully Navigating Global Cell Therapy Requirements."
CTMC Partners with ScaleReady for Combatting Manufacturing Barriers
October 6th 2023The agreement will enable CTMC to strategically scale the recently completed good manufacturing practice facility to drive high-throughput manufacturing utilizing the automated, closed system capabilities of the Fresenius Kabi Lovo and Cue cell processing systems.
Otsuka Collaborates with ShapeTX for Development of AAV Gene Therapies
September 14th 2023The companies are collaborating to apply ShapeTX’s AAVid capsid discovery platform and transgene engineering technology in addition to Otsuka’s expertise in genetic payload design and ophthalmology to develop novel treatment options for eye diseases.
Celularity Announces Research Collaboration with Regeneron
August 29th 2023The agreement focuses on the research of a targeted allogeneic gamma delta chimeric antigen receptor (CAR) T-cell therapy, owned by Regeneron, designed to enhance proliferation and potency against solid tumors, according to the press release.
Astellas and Poseida Therapeutics Plan to Invest in Redefining Cancer Cell Therapy
August 14th 2023Additionally, Poseida has approved Astellas as a board observer seat, which gives Astellas the right to attend Poseida’s scientific advisory board meetings and certain notice rights related to any potential change of control over Poseida.
Nexcella Begins Production of CAR-T Cell Therapy Engineering Batches at US Manufacturing Site
May 31st 2023The start of production of US engineering batches of NXC-201, a CAR-T cell therapy candidate in early clinical development, is the first step in transferring Nexcella’s existing manufacturing process to the United States.